What Artemida Pharma Limited does

Artemida Pharma Limited is a privately-held drug development consultancy registered in England and Wales (Company Number 9004411), founded in 2014 and headquartered at the Stevenage Bioscience Catalyst in Hertfordshire, UK. The firm delivers integrated, project-driven drug development services spanning four modules — Chemistry, Manufacturing and Controls (CMC); Clinical Services; Regulatory Services; and Pharmacovigilance — covering both small molecules and biological agents across oncology, autoimmune/anti-inflammatory, anti-infectives, and cardiovascular indications.

The company targets start-up biotech, biopharma, and mid-sized pharma clients that lack full in-house drug development capabilities, providing strategic consultancy and project management from early-phase development through NDA/MAA submissions. Service scope includes product development strategy, commercial evaluation, outsourcing strategy, KOL interactions, medical monitoring, DSMB setup, regulatory authority liaison, and document authoring for CTAs, IMPDs, INDs, and MAAs/NDAs. Revenue is generated through professional services engagements (consultancy and project management fees), with pricing not publicly disclosed and likely quote-based per engagement.

Artemida operates through a multi-country office footprint (Stevenage, Dublin via subsidiary Artemida Pharma Europe Limited, and the Strasbourg area of France) and extends its reach into Japan through a partnership with ShiftZero for oncology drug development services. The firm is led by Founder and Managing Partner Dr Sarah Arbe-Barnes and Chief Medical Officer and Managing Partner Dr Robert Miller, holds the Queen's Award for Enterprise in International Trade (2018), and is a member of the Oslo Cancer Cluster. Headcount is reported in the 1–10 range, and no external institutional investment, parent company, or disclosed revenue has been recorded in the available data.

Name

Artemida Pharma Limited

Legal name

Artemida Pharma Limited

Website

https://artemidapharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Artemida Pharma Limited is a UK-based drug development consultancy founded in 2014 that provides strategic and project management services across CMC, clinical, regulatory, and pharmacovigilance disciplines to start-up biotech, biopharma, and mid-sized pharma clients in the UK, Europe, and Japan.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development Consultancy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Drug development consultancy
• Clinical development services
• Regulatory affairs consulting
• Pharmacovigilance consulting
• CMC consulting services

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Strategic Drug Development Consultancy Services: Artemida Pharma generates revenue through providing strategic drug development consultancy and project management services to biotech and pharma clients. Services encompass clinical, regulatory, CMC (Chemistry, Manufacturing and Controls), and commercial expertise for small molecules and biological agents.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Artemida Pharma provides strategic drug development consultancy and project management services to start-up biotech, biopharma and mid-sized pharma companies. Its integrated offering spans CMC, clinical development, regulatory affairs, and pharmacovigilance for small molecules and biological agents, covering product development strategy, outsourcing, KOL engagement, medical monitoring, and global regulatory submissions.

Product overview

Artemida Pharma offers an integrated, end-to-end drug development consultancy providing four interconnected service modules: CMC (Chemistry, Manufacturing, and Controls), Clinical Services, Regulatory Services, and Pharmacovigilance Services. These services are designed to complement clients' skill-sets and resources, helping overcome obstacles in drug development pathways for small molecules and biological agents across oncology, autoimmune/anti-inflammatory, anti-infectives, and cardiovascular indications.

Differentiator

Problem solved

Functional benefit

Products and services

• CMC (Chemistry, Manufacturing and Controls) Services

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core and minor.

• ShiftZerocoreStrategic or Co-development PartnerArtemida Pharma partnered with ShiftZero to provide services in Japan, including oncology drug development expertise, Japanese drug development planning, Japanese regulatory consultation with authority interaction, clinical execution of oncology drug trials in Japan, and marketing services for oncology drug development in Japan.
• Oslo Cancer ClusterminorOthersArtemida Pharma is a member of the Oslo Cancer Cluster, an industry cluster supporting oncology drug development and collaboration in the Norwegian cancer research ecosystem.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Alacrita: Alacrita is a drug development consultancy providing strategic, clinical, regulatory, and commercial advice to biotech and pharma, with a particular focus on small and emerging companies. It is directly comparable to Artemida in business model, scale, and service mix, providing integrated drug development consulting across similar therapeutic areas.
• Boyne Biopharma Solutions: Boyne Biopharma Solutions is a small drug development consultancy providing CMC, regulatory, and project management services to biotech and pharma in Europe and internationally. It is directly comparable to Artemida in size, service mix, and senior-scientist-led consultancy model.
• PharmaLex: PharmaLex (now part of Cencora) is a regulatory affairs, pharmacovigilance, and CMC consulting firm serving pharma and biotech globally. It is one of the closest comparables to Artemida because both provide integrated regulatory strategy, CMC, and pharmacovigilance services across small molecules and biologics, with a similar consultancy-led delivery model.
• Quotient Sciences: Quotient Sciences is a drug development and manufacturing services provider offering formulation, clinical pharmacology, and CMC services for small molecules. It is comparable to Artemida because both serve biotech and pharma with integrated CMC and clinical drug development services across early-phase programs.
• Catenion: Catenion is a strategy consulting firm focused on pharmaceutical R&D and innovation strategy for biotech and pharma clients. It is comparable to Artemida because both operate as senior-scientist-led consultancies supporting biotech clients on drug development strategy and execution across therapeutic areas.
• Defined Health: Defined Health is a strategic communications and business development consultancy focused on emerging biotech and pharma. It is comparable to Artemida because both serve small-cap biotech clients with senior-led drug development strategy and commercialization advisory services.

Broad incumbents

• KCR: KCR is a clinical development and contract research services provider focused on biotech and mid-sized pharma across Europe and the US. It is comparable to Artemida because both target emerging biotech and mid-sized pharma with full-service clinical and regulatory drug development offerings.
• Celerion: Celerion is a clinical pharmacology CRO specializing in early-phase clinical research, bioanalytical services, and clinical development for pharma and biotech. It is comparable to Artemida because both serve small-to-mid pharma clients needing early-phase drug development expertise, particularly in clinical execution and pharmacokinetics support.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a global mid-sized CRO offering clinical, regulatory, and pharmacovigilance services to biotech and pharma. It is comparable to Artemida as a direct competitor in clinical and regulatory drug development services, though it operates at a much larger scale with broader geographic reach.
• Charles River Laboratories: Charles River Laboratories is a global CRO/CDMO offering discovery, safety assessment, CMC, and clinical trial services across the drug development value chain. It is comparable to Artemida as a broad incumbent competitor offering overlapping regulatory, CMC, and clinical capabilities, but at vastly greater scale and geographic reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/artemida-pharma-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artemida Pharma Limited